Kindred Biosciences to Present Data from Six Studies at the 2017 American College of Veterinary Internal Medicine Conference
San Francisco, CA (May 30, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will be presenting data from six studies at the 2017 American College of Veterinary Internal Medicine (ACVIM) conference in National Harbor, MD, held June 8-10, 2017. The Company will be sharing effectiveness and safety data from its Mirataz™ (mirtazapine transdermal ointment) and Zimeta™ (dipyrone injection) development programs and sponsoring scientific sessions. In addition, KindredBio will be sponsoring five Scientific Sessions at the conference.
“We are proud that all six of the abstracts we submitted to the ACVIM conference have been accepted. We are particularly excited to share the detailed effectiveness and safety data for both Mirataz and Zimeta. Additionally, we are pleased to be sponsoring scientific content presented by highly respected veterinary thought-leaders,” stated Richard Chin, M.D., CEO of KindredBio.
- Safety of Mirtazapine Transdermal Ointment Administered Topically to Cats at 5 mg/kg for 28 Days (P10)
- Double-Blind, Placebo-Controlled, Randomized Study of Mirtazapine Transdermal Ointment for the Management of Feline Weight Loss (P11)
- Single Dose Pharmacokinetics Following Transdermal Application and Oral Administration of Mirtazapine Ointment in Cats (P12)
- Multiple Dose Pharmacokinetics of Mirtazapine Transdermal Ointment in Cats (P13)
- A Randomized, Blinded, Placebo-Controlled, Crossover Study of Dipyrone to Control Fever in Horses (P54)
- A Placebo-Controlled Study of the Clinical Safety of an Oral Formulation of Dipyrone in Horses (P55)
KindredBio-Sponsored Scientific Sessions:
- Thursday, June 8th, 11:30 AM – 12:20 PM ET
Nutritional Management of Equine Gastric Ulcers: What Do We Really Know?
Frank Andrews, DVM, MS, DACVIM
- Friday, June 9th, 6:30 – 8:00 AM ET
Strategies for Management of Weight Loss and Cachexia in Cats
Jessica Quimby, DVM, PhD, DACVIM
- Friday, June 9th, 2:10 – 3:00 PM ET
Ataxia is Not the Only Clinical Manifestation of Neck Injuries
Jean Marie Denoix, DVM, PhD, ISELP Certified Instructor
- Friday, June 9th, 3:10 – 4:00 PM ET
Diagnosis of Low Back (Lumbar and Lumbosacral) Pain in Equine Athletes
Jean Marie Denoix, DVM, PhD, ISELP Certified Instructor
- Saturday, June 10th, 10:00 – 10:50 AM ET
The Old Horse: Medical Management with a Focus on PPID and Insulin Dysregulation
Harold Schott, DVM, PhD, DACVIM
Elizabeth Tadros, DVM
The Company will also be holding discussions with veterinarians interested in KindredBio’s pipeline at Booth #100 in the Exhibit Hall during ACVIM.
About Kindred Biosciences
Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our expectations about the trials, regulatory approval, manufacturing, distribution and commercialization of our current and future product candidates, and statements regarding our anticipated revenues, expenses, margins, profits and use of cash.
These forward-looking statements are based on our current expectations. These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results to be materially different from any future results expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: our limited operating history and expectations of losses for the foreseeable future; the absence of significant revenue from our product candidates for the foreseeable future; our potential inability to obtain any necessary additional financing; our substantial dependence on the success of our lead product candidates, which may not be successfully commercialized even if they are approved for marketing; the effect of competition; our potential inability to obtain regulatory approval for our existing or future product candidates; our dependence on third parties to conduct some of our development activities; our dependence upon third-party manufacturers for supplies of our product candidates; uncertainties regarding the outcomes of trials regarding our product candidates; our potential failure to attract and retain senior management and key scientific personnel; uncertainty about our ability to develop a satisfactory sales organization; our significant costs of operating as a public company; our potential inability to obtain patent protection and other intellectual property protection for our product candidates; potential claims by third parties alleging our infringement of their patents and other intellectual property rights; our potential failure to comply with regulatory requirements, which are subject to change on an ongoing basis; the potential volatility of our stock price; and the significant control over our business by our principal stockholders and management.
For a further description of these risks and other risks that we face, please see the risk factors described in our filings with the U.S. Securities and Exchange Commission (the SEC), including the risk factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K and any subsequent updates that may be contained in our Quarterly Reports on Form 10-Q filed with the SEC. As a result of the risks described above and in our filings with the SEC, actual results may differ materially from those indicated by the forward-looking statements made in this press release. Forward-looking statements contained in this press release speak only as of the date of this press release and we undertake no obligation to update or revise these statements, except as may be required by law.